Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
AVITA Medical develops and commercializes regenerative medicine products for skin restoration, primarily the RECELL System which uses a patient's own skin cells to treat burns, vitiligo, and other skin defects. The company operates in the US, Australia, and select international markets with a direct sales force targeting burn centers and plastic surgery practices. Currently pre-profitability with high gross margins but significant operating losses as it scales commercial infrastructure.
AVITA operates a razor-razorblade model where hospitals purchase the RECELL device capital equipment, then generate recurring revenue through single-use processing kits required for each patient treatment. The company targets high-value burn centers and plastic surgery practices with direct sales teams, emphasizing clinical outcomes data showing reduced donor site requirements and faster healing versus traditional skin grafting. Pricing power derives from FDA clearance, clinical differentiation, and lack of direct autologous cell therapy competitors, though traditional split-thickness skin grafting remains the standard of care. The 82% gross margin reflects low manufacturing costs for disposable kits versus premium pricing, but the company burns significant cash on sales force expansion and clinical education programs.
Quarterly device placements and utilization rates at existing burn center accounts
FDA label expansion decisions for new indications beyond burns (vitiligo, surgical reconstruction)
Reimbursement coverage decisions from major payers (CMS, United, Anthem) affecting adoption economics
Clinical trial readouts demonstrating superiority versus standard of care in cost-effectiveness studies
International partnership announcements and regulatory approvals in new geographies
Reimbursement uncertainty as payers scrutinize cost-effectiveness versus traditional skin grafting, with potential for restrictive coverage policies limiting addressable market
Regulatory pathway complexity for new indications requiring expensive clinical trials and lengthy FDA review processes, delaying revenue diversification
Technology obsolescence risk from competing regenerative medicine approaches including bioprinted skin, stem cell therapies, or improved synthetic skin substitutes
Entrenched standard of care with split-thickness skin grafting representing low-cost, well-understood alternative that surgeons are trained on and comfortable using
Large medical device incumbents (Smith+Nephew, Integra LifeSciences) with established burn care portfolios and superior sales force scale could develop competing autologous cell technologies
International competitors with regulatory approvals in ex-US markets limiting global expansion opportunities
Critical liquidity concerns with 0.57 current ratio indicating working capital deficit and negative operating cash flow requiring near-term financing
Equity dilution risk as the company likely needs additional capital raises before reaching profitability, with 1-2 year estimated cash runway based on current burn rate
Negative tangible book value (-7.9x price/book) reflecting accumulated losses, providing no liquidation value cushion for investors
low - Burn treatment demand is non-discretionary and driven by trauma incidents rather than economic conditions. Elective procedures for vitiligo and cosmetic applications show moderate sensitivity to consumer discretionary spending, but currently represent minimal revenue. Hospital capital equipment budgets can tighten during recessions, potentially delaying initial device placements, though the relatively low capital cost ($15-25K estimated) limits this impact.
Rising rates create moderate headwinds through two channels: (1) higher discount rates compress valuation multiples for pre-profitable growth companies, disproportionately affecting stocks trading on forward revenue multiples rather than earnings; (2) hospital systems face higher borrowing costs for capital equipment purchases, though RECELL's modest price point limits this effect. The company's negative cash flow means it may need to raise capital at less favorable terms in a high-rate environment.
Minimal direct exposure. AVITA sells primarily to well-capitalized hospital systems with strong credit profiles. The company's own credit needs are limited given minimal debt ($0.13 debt/equity ratio suggests net cash position), though future growth capital requirements could necessitate dilutive equity raises or debt financing if operating losses persist.
growth - Attracts speculative biotech/medtech investors focused on FDA approval catalysts, clinical data readouts, and revenue inflection potential rather than current profitability. The -57.8% one-year return and high volatility appeal to momentum traders around binary events. Not suitable for value or income investors given negative earnings, no dividends, and balance sheet concerns. Institutional ownership likely concentrated in healthcare-focused funds willing to underwrite 3-5 year commercialization timelines.
high - Small-cap pre-profitable medical device company with binary regulatory and reimbursement catalysts creates significant price volatility. The $100M market cap and likely limited float amplify moves on news flow. Clinical trial results, FDA decisions, and quarterly revenue surprises versus expectations drive 20-40% single-day moves. Beta likely exceeds 1.5x relative to broader market given growth stock characteristics and sector-specific risk factors.
